

## Synthesis of methyl 2-[2-(alkylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate derivatives under solvent-free condition

Rahimeh Hajinasiri<sup>a,\*</sup>, Sobhan Rezayati<sup>a,b</sup>

<sup>a</sup>Department of Chemistry, Islamic Azad University, Qaemshahr Branch, P.O. BOX 163, Qaemshahr, Iran

<sup>b</sup>Department of Chemistry, Payame Noor University, P.O. BOX 19395-4697 Tehran, Iran

Received: 5 September 2014, Accepted: 28 September 2014, Published: 1 January 2015

### Abstract

An efficient synthesis of Methyl 2-[2-(alkylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate derivatives *via* simple three-component reaction and one-pot reactions between isoquinoline, dimethyl acetylenedicarboxylate and *N*-phenylthiourea is described under solvent-free conditions without using any additional catalyst.

**Keywords:** Isoquinoline; solvent-free; *N*-phenylthiourea; thiazolan; green chemistry.

### Introduction

Multicomponent reactions (MCRs) are defined by three or more reactants joining in a one-pot procedure to afford a single product [1-4]. They are economically and environmentally useful because multi-step syntheses frequently produce a large amount of waste and also the complex isolation actions often involve uncomfortable, toxic, and hazardous solvents after each step [5-8]. MCRs are absolutely suited for combinatorial

library synthesis and are increasingly utilized in discovery of new drugs and agrochemicals [9]. They represent a useful tool toward the one-pot synthesis of diverse and complex compounds as well as small and drug-like heterocycles [10 and 11]. Heterocycles are key compounds in the development of modern pharmaceutical chemistry, which is the reason why the design of amenable synthetic approaches for new heterocyclic systems is still significant challenge [12].

\*Corresponding author: Rahimeh Hajinasiri

Tel: +98 (11) 42253216-19, Fax: +98 (11) 42253216

E-mail: [rhmhajinasiri@yahoo.com](mailto:rhmhajinasiri@yahoo.com)


The thiazolium ring present in vitamin B1 serves as an electron sink and its coenzyme form is important for the decarboxylation of keto-acids [13]. Several pesticides possessing a heterocycle with an S or an N atom are known in agriculture. A large number of heterocycles has been emerged as active pharmaceutical ingredients in several drugs for their potential anti-inflammatory [14], anti-tumour [15] anti-hyperlipidemic [16], anti-hypertensive [17], anti-HIV infections [18], and several other biological properties

[19 and 20]. Herein, we report the synthesis of methyl 2-[2-(alkylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden] acetate derivatives **4** via the reaction of isoquinoline **1**, dialkyl acetylenedicarboxylates **2** and phenylthiourea **3** which proceed smoothly under solvent-free conditions at room temperature (Figure 1).

## Experimental

### General

All chemicals used in this work were purchased from Fluka (Buchs, Switzerland) and used without further purification.



**Figure 1.** Synthesis of compounds **4a-g**.

Elemental analyses for C, H, and N were performed using a Heraeus CHN–O-Rapid analyzer. Mass spectra were recorded on a FINNIGAN-MAT 8430 spectrometer operating at an ionization potential of 70 eV.

IR spectra were measured on a Shimadzu IR-460 spectrometer.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were measured with a BRUKER DRX-400 AVANCE spectrometer at 400 and 100 MHz, respectively.  $^1\text{H}$  and  $^{13}\text{C}$  spectra were

obtained for solutions in CDCl<sub>3</sub> using TMS as the internal standard.

**General procedure for synthesis of 4a-4g.**

Dimethyl acetylenedicarboxylate **2** (2 mmol) was slowly added to a magnetically stirred mixture of phenylthiourea **3** (2 mmol) and isoquinoline **1** (2 mmol), and the reaction mixture was stirred for 4 h at room temperature. After completion of the reaction, as indicated by TLC, the residue was purified by chromatography over silica gel (Merck 230-400 mesh) using an n-hexane-AcOEt mixture (12:1) as eluant to afford the pure compound **4**.

**Methyl 2-[2-(ethylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4a).**

Yellow powder; m.p. 150-152 °C, yield: 0.49 g (85 %). IR (KBr): 1718 (C=O), 1733 (C=O), 2976 (CH) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.17 (t, 3 H, <sup>3</sup>J = 7.0 Hz, CH<sub>3</sub>), 3.64 (q, 2 H, <sup>3</sup>J = 7.0 Hz, CH<sub>2</sub>), 3.73 (s, 3 H, OCH<sub>3</sub>), 6.83 (s, 1 H, CH), 6.91 (dd, 2 H, <sup>3</sup>J = 8.6 Hz, <sup>3</sup>J = 1.2 Hz, 2 CH), 7.11 (t, 1 H, <sup>3</sup>J = 7.6 Hz, CH), 7.28 (dd, 2 H, <sup>3</sup>J = 9.0 Hz, <sup>3</sup>J = 8.6 Hz, 2 CH). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 18.4 (Me), 52.5 (OMe), 58.4 (NCH<sub>2</sub>), 116.0 (CH), 121.0 (2 CH), 125.3 (CH), 129.4 (2 CH), 141.7 (C), 147.2 (C), 151.5 (C=N), 165.0 (C=O), 166.4 (C=O). MS: *m/z* (%) = 290 (3) [M<sup>+</sup>], 178 (12), 144 (40), 43 (100). Anal. Calcd for

C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>S (290.34): C 57.92, H 4.86, N 9.65; found C 58.12, H 4.52, N 9.34 %.

**Methyl 2-[2-(methylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4b).**

Yellow powder, m.p. 147-149 °C; yield: 0.48 g (87 %). IR (KBr): 1715 (C=O), 1734 (C=O), 2966 (CH) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.63 (s, NCH<sub>3</sub>), 3.72 (s, 3 H, OCH<sub>3</sub>), 6.83 (s, 1 H, CH), 6.92 (dd, 2 H, <sup>3</sup>J = 8.8 Hz, <sup>3</sup>J = 1.3 Hz, 2 CH), 7.10 (t, 1 H, <sup>3</sup>J = 8.0 Hz, CH), 7.29 (dd, 2 H, <sup>3</sup>J = 8.6 Hz, <sup>3</sup>J = 8.7 Hz, 2 CH). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 51.5 (OCH<sub>3</sub>), 57.4 (NCH<sub>3</sub>), 114.8 (CH), 120.0 (2 CH), 124.2 (CH), 128.4 (2 CH), 140.9 (C), 146.3 (C), 149.7 (C=N), 163.7 (C=O), 165.3 (C=O). MS: *m/z* (%) = 276 (3) [M<sup>+</sup>], 247 (22), 217 (78), 199 (37), 59 (100). Anal. Calcd for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S (276.31): C 56.51, H 4.38, N 10.14; found C 56.21, H 4.47, N 9.93 %.

**Methyl 2-[2-(isopropylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4c).**

Yellow powder, m.p. 153-155 °C; yield: 0.54 g (90 %). IR (KBr): 1721 (C=O), 1738 (C=O), 2975 (CH) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.18 (d, 6 H, <sup>3</sup>J = 7.0 Hz, 2 CH<sub>3</sub>), 3.68 (heptet, 1 H, CH, <sup>3</sup>J = 6.0 Hz), 3.89 (s, 3 H, OCH<sub>3</sub>), 6.98 (s, 1 H, CH), 7.05 (dd, 2 H, <sup>3</sup>J = 8.0 Hz, <sup>3</sup>J = 1.2 Hz, 2 CH),

7.12 (t, 1 H,  $^3J = 7.6$  Hz, CH), 7.23 (dd, 2 H,  $^3J = 8.8$  Hz,  $^3J = 8.6$  Hz, 2 CH).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  21.5 (2 Me), 51.8 (OMe), 58.1 (CH), 115.1 (CH), 120.8 (2 CH), 125.3 (CH), 128.7 (2 CH), 141.7 (C), 147.1 (C), 151.0 (C=N), 165.3 (C=O), 166.2 (C=O). MS:  $m/z$  (%) = 304 (3) [ $\text{M}^+$ ], 289 (18), 245 (83), 227 (44), 59 (100). Anal. Calcd for  $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_3\text{S}$  (304.36): C 59.19, H 5.30, N 9.20; found C 59.31, H 5.08, N 9.30%.

**Methyl 2-[2-(butylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4d).**

Yellow powder, m.p. 155-157 °C; yield: 0.54 g (85 %). IR (KBr): 1715 (C=O), 1741 (C=O), 2986 (CH)  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.99 (t, 3 H,  $^3J = 7.2$  Hz,  $\text{CH}_3$ ), 1.76 (sixtet,  $^3J = 7.2$  Hz, 2 H,  $\text{CH}_2$ ), 1.43 (quintet,  $^3J = 7.2$  Hz, 2 H,  $\text{CH}_2$ ), 3.82 (s, 3 H,  $\text{OCH}_3$ ), 3.99 (t, 1 H,  $^3J = 7.2$  Hz,  $\text{CH}_2$ ), 6.92 (s, 1 H, CH), 7.04 (dd, 2 H,  $^3J = 8.3$  Hz,  $^3J = 1.3$  Hz, 2 CH), 7.13 (t, 1 H,  $^3J = 7.8$  Hz, CH), 7.21 (dd, 2 H,  $^3J = 8.6$  Hz,  $^3J = 8.9$  Hz, 2 CH).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  14.1 (Me), 21.3 ( $\text{CH}_2$ ), 31.5 ( $\text{CH}_2$ ), 52.3 (OMe), 57.9 (CH), 116.1 (CH), 121.2 (2 CH), 125.8 (CH), 129.5 (2 CH), 141.8 (C), 147.3 (C), 151.5 (C=N), 165.3 (C=O), 166.2 (C=O). MS:  $m/z$  (%) = 318 (5) [ $\text{M}^+$ ], 267 (26), 259 (68), 241 (31), 59 (100). Anal. Calcd for  $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$  (318.39): C 60.36,

H 5.70, N 8.80; found C 60.20, H 5.45, N 9.08%.

**Methyl 2-[2-(isobutylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4e).**

Yellow powder, m.p. 154-156 °C; yield: 0.54 g (85 %). IR (KBr): 1718 (C=O), 1735 (C=O), 2981 (CH)  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.96 (t, 3 H,  $^3J = 7.0$  Hz, 2  $\text{CH}_3$ ), 1.88–2.05 (m, 1 H, CH), 3.66 (d, 1 H,  $^3J = 6.9$  Hz, CH), 3.72 (s, 3 H,  $\text{OCH}_3$ ), 6.84 (s, 1 H, CH), 6.91 (dd, 2 H,  $^3J = 8.5$  Hz,  $^3J = 1.2$  Hz, 2 CH), 7.12 (t, 1 H,  $^3J = 7.8$  Hz, CH), 7.26 (dd, 2 H,  $^3J = 8.6$  Hz,  $^3J = 8.9$  Hz, 2 CH).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  19.1 (2 Me), 26.1 ( $\text{CH}_2$ ), 52.4 (OMe), 58.3 (CH), 116.8 (CH), 121.0 (2 CH), 125.4 (CH), 129.4 (2 CH), 141.7 (C), 147.5 (C), 151.3 (C=N), 165.3 (C=O), 166.4 (C=O). MS:  $m/z$  (%) = 318 (5) [ $\text{M}^+$ ], 267 (34), 259 (73), 241 (48), 59 (100). Anal. Calcd for  $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$  (318.39): C 60.36, H 5.70, N 8.80; found C 60.19, H 5.83, N 8.93%.

**Methyl 2-[2-(propylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4f).**

Yellow powder, m.p. 151-153 °C; yield: 0.55 g (93 %). IR (KBr): 1725 (C=O), 1735 (C=O), 2985 (CH)  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.91 (t, 3 H,  $^3J = 7.0$  Hz, 2  $\text{CH}_3$ ), 1.75- 1.78 (m, 2 H,  $^3J = 7.0$  Hz,  $\text{CH}_2$ ), 3.64 (t, 1 H,  $^3J = 6.9$  Hz, CH), 3.73 (s, 3 H,

OCH<sub>3</sub>), 6.83 (s, 1 H, CH), 6.90 (dd, 2 H, <sup>3</sup>J = 8.5 Hz, <sup>3</sup>J = 1.2 Hz, 2 CH), 7.10 (t, 1 H, <sup>3</sup>J = 7.8 Hz, CH), 7.24 (dd, 2 H, <sup>3</sup>J = 8.6 Hz, <sup>3</sup>J = 8.9 Hz, 2 CH). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 10.7 (Me), 23.8 (CH<sub>2</sub>), 23.8 (CH<sub>2</sub>), 52.5 (OMe), 58.2 (CH), 114.1 (CH), 121.2 (2 CH), 125.3 (CH), 129.1 (2 CH), 141.6 (C), 147.4 (C), 151.5 (C=N), 165.3 (C=O), 166.4 (C=O). EI-MS: *m/z* (%) = 304 (3) [M]<sup>+</sup>, 289 (21), 245 (75), 227 (36), 59 (100). Anal. Calcd for C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S (304.36): C 59.19, H 5.30, N 9.20; found C 58.90, H 5.41, N 9.03%.

**Methyl 2-[2-(cyclohexylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate (4g).**


Yellow powder, m.p. 163-165 °C; yield: 0.62 g (90 %). IR (KBr): 1720 (C=O), 1733 (C=O), 2983 (CH) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.54–1.58 (m, 2 H, CH<sub>2</sub>), 1.68–1.73 (m, 4 H, 2 CH<sub>2</sub>), 1.87–1.93 (m, 4 H, 2 CH<sub>2</sub>), 3.65 (t, 1 H, <sup>3</sup>J = 6.9 Hz, CH), 3.73 (s, 3 H, OCH<sub>3</sub>), 6.84 (s, 1 H, CH), 6.90 (dd, 2 H, <sup>3</sup>J = 8.5 Hz, <sup>3</sup>J = 1.2 Hz, 2 CH), 7.11 (t, 1 H, <sup>3</sup>J = 7.8 Hz, CH), 7.28 (dd, 2 H, <sup>3</sup>J = 8.6 Hz, <sup>3</sup>J = 8.9 Hz, 2 CH). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 23.2 (2 CH<sub>2</sub>), 25.1 (CH<sub>2</sub>), 31.0 (2 CH<sub>2</sub>), 52.4 (OMe), 58.4 (CH), 116.2 (CH), 121.0 (2 CH), 125.6

(CH), 129.0 (2 CH), 141.6 (C), 147.4 (C), 151.5 (C=N), 165.4 (C=O), 166.5 (C=O). MS: *m/z* (%) = 344 (5) [M<sup>+</sup>], 285(69), 261 (18), 227 (34), 59 (100). Anal. Calcd for C<sub>18</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S (344.43): C 62.77, H 5.85, N 8.13; found C 62.86, H 5.71, N 8.24 %.

**Results and discussion**

The structures of **4a-g** compounds were apparent from the <sup>1</sup>H NMR, <sup>13</sup>C NMR and IR spectra. The <sup>1</sup>H NMR spectrum of **4a** exhibited all expected signals at δ 1.17 and 3.64 ppm for the ethyl moiety, broad singlet peak at δ 1.52, two singlet peaks at δ 3.37 and 3.72 ppm for two methoxy groups and a singlet at δ 6.85 ppm for an olefinic proton along with signals for the phenyl units at 6.90–7.31 ppm. The proton-decoupled <sup>13</sup>C NMR spectrum of **4a** showed 13 distinct resonances in agreement with the proposed structure.

A possible mechanism for this reaction is proposed in Figure 2. The zwitterionic intermediate **6** produced from the reaction of isoquinoline and dialkyl acetylenedicarboxylate is subsequently protonated by a phenylthiourea **3**, then attacked by the conjugate base of the phenylthiourea and cyclized to produce **4**.



**Figure 2.** Possible mechanism for the formation of compounds **4**.

## Conclusion

In conclusion, we have reported a convenient one-pot route for the synthesis of methyl 2-[2-(alkylimino)-4-oxo-3-phenyl-1,3-thiazolan-5-yliden]acetate by reaction of isoquinoline, dimethyl acetylenedicarboxylate and phenylthiourea, at solvent-free conditions and r.t.

## Acknowledgments

We gratefully acknowledge financial and spiritual support from Islamic Azad University of Qaemshahr.

## References

- [1] A. Domling, *Comb. Chem. High. T. Scr.*, **1998**, *1*, 1-22.
- [2] A. Domling, I. Ugi, *Angew. Chem. Int. Ed.*, **2000**, *39*, 3168.
- [3] L. Weber, *Drug Discovery Today*, **2002**, *7*, 143-147.
- [4] A. Shaabani, A. Maleki, A.H. Rezayan, A. Sarvary, *Mol. Divers.*, **2011**, *15*, 41-68.
- [5] J. Zhu, H. Bienayme, *Multicomponent Reactions*, Eds. Wiley-VCH, Weinheim, Germany, **2005**.
- [6] P. Wipf, C. Kendall, *Chem. Eur. J.*, **2002**, *8*, 1778-1784.
- [7] G. Balme, E. Bossharth, N. Monteiro, *Eur. J. Org. Chem.*, **2003**, 4101-4111.
- [8] A. Jacobi von Wangelin, H. Neumann, D. Gordes, S. Klaus, D. Strubing, M. Beller, *Chem. Eur. J.*, **2003**, *9*, 4286-4294.
- [9] S. Heck, A. Domling, *Synlett.*, **2000**, 424-426.
- [10] L. Weber, *Curr. Med. Chem.*, **2002**, *9*, 2085-2093.
- [11] I. Yavari, A.S. Shahvelayati, A. Malekafzali, *Journal of Sulfur Chemistry*, **2010**, *31*, 499-508.
- [12] P.M. Dewick, *Medicinal natural products. A biosynthetic approach*, 2nd eds; Wiley, Chichester, U.K. **2002**.
- [13] (a) R. Breslow, *J. Am. Chem. Soc.*, **1958**, *80*, 3719-3726. (b) I. Yavari, S. A. Asgari, K. Porshamsian, M. Bagheri, *J.*

- Sulfur. Chem.*, **2007**, *28*, 477-482. (c) I. Yavari, M. Sabaghan, S. A. Asgari, K. Porshamsian, M. Bagheri, Z. Hossaini, *Mol. Diversity*, **2007**, *11*, 81-85.
- [14] S. Miwatashi, Y. Arikawa, E. Kotani, M. Miyamoto, K.I. Naruo, H. Kimura, T. Tanaka, S. Asahi, S. Ohkawa, *J. Med. Chem.*, **2005**, *48*, 5966-5979.
- [15] Y. Kumar, R. Green, K.Z. Borysko, D.S. Wise, L.L. Wotring, L.B. Townsend, *J. Med. Chem.*, **1993**, *36*, 3843-3848.
- [16] R. Pereira, C. Gaudon, B. Iglesias, P. Germain, H. Gronemeyer, A.R. de Lera, *Bioorg. Med. Chem. Lett.*, **2006**, *16*, 49-54.
- [17] Y. Tsurumi, H. Ueda, K. Hayashi, S. Takase, M. Nishikawa, S. Kiyoto, M. Okuhara, *J. Antibiotic*, **1995**, *48*, 1066-1072.
- [18] F.W. Bell, A.S. Cantrell, M. Hoberg, S.R. Jaskunas, N.G. Johansson, C.L. Jordon, M.D. Kinnick, P. Lind, J.M. Morin, *J. Med. Chem.*, **1995**, *38*, 4929-4936.
- [19] D.S. Millan, R.H. Prager, C. Brand, P.H. Hart, *Tetrahedron*, **2000**, *56*, 811-816.
- [20] W.L. Wang, D.Y. Yao, M. Gu, M.Z. Fan, J.Y. Li, Y.C. Xing, F.J. Nan, *Bioorg. Med. Chem. Lett.*, **2005**, *15*, 5284-5287.